[{"id":"c7ba05df-48e5-4170-b8f3-f78ce52e05e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05682170","created_at":"2023-01-12T15:02:24.531Z","updated_at":"2024-07-02T16:35:04.517Z","phase":"Phase 1/2","brief_title":"Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05682170","lead_sponsor":"K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azenosertib (ZN-c3) • asaretoclax (ZN-d5)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-05-10"},{"id":"8d1d5007-f79b-4123-b316-e22fd210c5a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04500587","created_at":"2023-04-07T16:03:19.605Z","updated_at":"2024-07-02T16:35:16.328Z","phase":"Phase 1","brief_title":"Phase 1 First in Human Study of ZN-d5 as a Single Agent","source_id_and_acronym":"NCT04500587","lead_sponsor":"K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e asaretoclax (ZN-d5)"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 10/13/2020","start_date":" 10/13/2020","primary_txt":" Primary completion: 08/02/2024","primary_completion_date":" 08/02/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-05"}]